Monitor for upcoming earnings or regulatory filings, this level of coordinated C-suite selling often precedes negative news. Consider this a warning sign, especially given the CEO's significant participation.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 2 $5.16entry
- T+1 · 9mo ago −1.16%α −0.25% · $5.10
- T+5 · 8mo ago +2.71%α +3.92% · $5.30
- T+20 · 8mo ago −0.39%α +7.55% · $5.14
- T+60 · 6mo ago +27.71%α +18.39% · $6.59
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three top executives at Teladoc Health, including CEO Charles Divita and the Chief Legal Officer, sold shares in a coordinated open-market transaction totaling $531,528 over a two-day window. All sales occurred at $5.117 per share, representing material insider selling by C-suite leadership.
Key Financial Metrics
Key Facts
- CEO Charles Divita sold $256,600 worth of shares in an open-market transaction.
- Chief Legal Officer and President of U.S. Group Health sold an additional $275,000 combined.
- Total open-market sales: $531,528 over 7 days by three C-suite executives.
- All sales were at $5.117 per share, indicating deliberate monetization, not automatic withholding.
- Each insider also exercised derivative securities (non-cash) on the same day, likely triggering the sale window.
Financial Impact
$531,528 in insider selling over 7 days, representing ~0.058% of Teladoc's $921M market cap
Risk Factors
- Insiders may have material non-public information suggesting near-term downside.
- Perception of lack of confidence from top leadership could pressure stock sentiment.
- Potential for follow-on selling if other insiders exit positions.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-TDOC-1772572482584 |
Track record
24 reports on TDOC
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $8.60 Now $8.70 +1.22% settles Nov 17
- Nov 6, 202610d ago 144 Neutral 3/10 Entry $8.77 to $8.98 Now $8.70 −0.80% ▲ +2.39% +0.03% vs SPY
- Nov 3, 202613d ago 3 / PRESS-RELEASE Neutral 2/10 Entry $9.70 to $9.41 Now $8.70 −10.31% ▼ −2.99% +1.42% vs SPY
- Nov 3, 202614d ago PTAB Trial Neutral 3/10 Entry $8.89 to $9.70 Now $8.70 −2.14% ▲ +9.11% +7.46% vs SPY
- Oct 28, 202619d ago Press Release Bearish 6/10 No price data
- Oct 28, 202619d ago 8-K Bearish 6/10 Entry $8.73 to $8.51 Now $8.70 +0.34% ▲ +2.52% +0.75% vs SPY
- Oct 28, 202620d ago PTAB Trial Neutral 3/10 Entry $8.73 to $8.51 Now $8.70 −0.34% ▼ −2.52% −0.75% vs SPY
- Oct 8, 20265w ago SC 13G Neutral 3/10 Entry $5.54 to $5.77 Now $8.70 +57.04% ▲ +4.15% +3.55% vs SPY
- Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.09 to $5.89 Now $8.70 +42.86% ▼ −3.28% −2.54% vs SPY
- Sep 11, 20269w ago 144 Neutral 2/10 Entry $6.16 to $6.50 Now $8.70 +41.23% ▲ +5.52% +5.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers